Do analysts rate TAK or NBIX?

Neurocrine Biosciences has a consensus target price of $201.05, indicating a potential upside of 26.96%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Neurocrine Biosciences 0 Sell rating(s) 4 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media favor TAK or NBIX?

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 4 mentions for Takeda Pharmaceutical. Neurocrine Biosciences' average media sentiment score of 1.28 beat Takeda Pharmaceutical's score of 0.45 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ONC or NBIX?

In the previous week, Neurocrine Biosciences had 16 more articles in the media than BeOne Medicines. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 5 mentions for BeOne Medicines. Neurocrine Biosciences' average media sentiment score of 1.28 beat BeOne Medicines' score of 0.53 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NBIX or RPRX?

In the previous week, Neurocrine Biosciences had 13 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 8 mentions for Royalty Pharma. Neurocrine Biosciences' average media sentiment score of 1.28 beat Royalty Pharma's score of 0.47 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to NBIX or ZTS?

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Zoetis. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 17 mentions for Zoetis. Zoetis' average media sentiment score of 1.50 beat Neurocrine Biosciences' score of 1.28 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 16 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neurocrine Biosciences (NBIX) Competitors

$158.35 +0.56 (+0.35%)

As of 04:00 PM Eastern

Compare

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

Should you buy Neurocrine Biosciences stock or one of its competitors? Neurocrine Biosciences's main competitors and comparable companies include Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Neurocrine Biosciences has a consensus target price of $201.05, indicating a potential upside of 26.96%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has a net margin of 20.91% compared to Takeda Pharmaceutical's net margin of 3.80%. Neurocrine Biosciences' return on equity of 22.43% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Neurocrine Biosciences	20.91%	22.43%	15.64%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neurocrine Biosciences has lower revenue, but higher earnings than Takeda Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.12	-$1.01B	$0.34	55.03
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.22

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 4 mentions for Takeda Pharmaceutical. Neurocrine Biosciences' average media sentiment score of 1.28 beat Takeda Pharmaceutical's score of 0.45 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Neurocrine Biosciences (NASDAQ:NBIX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neurocrine Biosciences has a net margin of 20.91% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Neurocrine Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for Teva Pharmaceutical Industries and 21 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.28 beat Teva Pharmaceutical Industries' score of 0.93 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	12 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.22
Teva Pharmaceutical Industries	$17.26B	2.47	$1.41B	$0.60	60.97

Neurocrine Biosciences currently has a consensus target price of $201.05, indicating a potential upside of 26.96%. Teva Pharmaceutical Industries has a consensus target price of $42.22, indicating a potential upside of 15.42%. Given Neurocrine Biosciences' higher probable upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Neurocrine Biosciences beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

BeOne Medicines has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

BeOne Medicines presently has a consensus target price of $402.14, suggesting a potential upside of 10.88%. Neurocrine Biosciences has a consensus target price of $201.05, suggesting a potential upside of 26.96%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has a net margin of 20.91% compared to BeOne Medicines' net margin of 10.70%. Neurocrine Biosciences' return on equity of 22.43% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Neurocrine Biosciences has lower revenue, but higher earnings than BeOne Medicines. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.45	$286.93M	$5.68	63.85
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.22

In the previous week, Neurocrine Biosciences had 16 more articles in the media than BeOne Medicines. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 5 mentions for BeOne Medicines. Neurocrine Biosciences' average media sentiment score of 1.28 beat BeOne Medicines' score of 0.53 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Royalty Pharma?

Neurocrine Biosciences (NASDAQ:NBIX) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 13 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 8 mentions for Royalty Pharma. Neurocrine Biosciences' average media sentiment score of 1.28 beat Royalty Pharma's score of 0.47 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Royalty Pharma has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.22
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06

Neurocrine Biosciences currently has a consensus price target of $201.05, suggesting a potential upside of 26.96%. Royalty Pharma has a consensus price target of $60.86, suggesting a potential downside of 4.73%. Given Neurocrine Biosciences' higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Neurocrine Biosciences' net margin of 20.91%. Royalty Pharma's return on equity of 30.01% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Royalty Pharma	32.14%	30.01%	14.91%

Neurocrine Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Royalty Pharma on 9 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Zoetis?

Neurocrine Biosciences (NASDAQ:NBIX) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Zoetis has higher revenue and earnings than Neurocrine Biosciences. Zoetis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.22
Zoetis	$9.47B	3.33	$2.67B	$6.07	12.58

In the previous week, Neurocrine Biosciences had 4 more articles in the media than Zoetis. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 17 mentions for Zoetis. Zoetis' average media sentiment score of 1.50 beat Neurocrine Biosciences' score of 1.28 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	16 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences presently has a consensus price target of $201.05, suggesting a potential upside of 26.96%. Zoetis has a consensus price target of $107.43, suggesting a potential upside of 40.72%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Neurocrine Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zoetis has a net margin of 27.49% compared to Neurocrine Biosciences' net margin of 20.91%. Zoetis' return on equity of 74.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Zoetis	27.49%	74.89%	18.59%

Summary

Zoetis beats Neurocrine Biosciences on 9 of the 17 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBIX vs. The Competition

Export

Metric	Neurocrine Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.10B	$12.26B	$7.24B	$12.90B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	23.22	787.27	273.57	25.42
Price / Sales	4.77	955.06	675.05	123.41
Price / Cash	31.27	92.66	76.98	52.08
Price / Book	4.36	12.41	12.91	6.15
Net Income	$478.60M	$2.82B	$3.47B	$349.01M
7 Day Performance	1.56%	1.97%	-0.46%	-1.48%
1 Month Performance	-4.74%	4.89%	6.40%	2.46%
1 Year Performance	16.34%	9.07%	24.88%	15.76%

Neurocrine Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBIX Neurocrine Biosciences	4.9352 of 5 stars	$158.35 +0.4%	$201.05 +27.0%	+11.2%	$16.10B	$3.37B	23.22	2,000	Positive News Analyst Forecast
TAK Takeda Pharmaceutical	1.4529 of 5 stars	$18.24 +0.3%	N/A	+21.6%	$58.25B	$28.32B	53.64	47,000
TEVA Teva Pharmaceutical Industries	3.8483 of 5 stars	$36.96 -1.0%	$42.22 +14.2%	+99.7%	$43.51B	$17.26B	61.60	33,950	Trending News
ONC BeOne Medicines	3.7632 of 5 stars	$371.98 -0.7%	$402.14 +8.1%	+9.0%	$41.11B	$5.34B	65.49	12,000
RPRX Royalty Pharma	3.4219 of 5 stars	$61.33 +0.0%	$60.86 -0.8%	+74.5%	$35.25B	$2.38B	42.30	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Summary

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Summary

How does Neurocrine Biosciences compare to BeOne Medicines?

Summary

How does Neurocrine Biosciences compare to Royalty Pharma?

Summary

How does Neurocrine Biosciences compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Do analysts rate TAK or NBIX?

Is TAK or NBIX more profitable?

Do insiders and institutionals have more ownership in TAK or NBIX?

Which has higher earnings and valuation, TAK or NBIX?

Does the media favor TAK or NBIX?

Which has more volatility & risk, TAK or NBIX?

Summary

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Do institutionals and insiders have more ownership in NBIX or TEVA?

Is NBIX or TEVA more profitable?

Which has more risk and volatility, NBIX or TEVA?

Does the media prefer NBIX or TEVA?

Which has better valuation and earnings, NBIX or TEVA?

Do analysts recommend NBIX or TEVA?

Summary

How does Neurocrine Biosciences compare to BeOne Medicines?

Which has more risk and volatility, ONC or NBIX?

Do analysts rate ONC or NBIX?

Is ONC or NBIX more profitable?

Which has stronger earnings & valuation, ONC or NBIX?

Does the media favor ONC or NBIX?

Do insiders & institutionals hold more shares of ONC or NBIX?

Summary

How does Neurocrine Biosciences compare to Royalty Pharma?

Do institutionals & insiders believe in NBIX or RPRX?

Does the media prefer NBIX or RPRX?

Which has stronger valuation and earnings, NBIX or RPRX?

Do analysts rate NBIX or RPRX?

Is NBIX or RPRX more profitable?

Which has more volatility & risk, NBIX or RPRX?

Summary

How does Neurocrine Biosciences compare to Zoetis?

Which has better valuation & earnings, NBIX or ZTS?

Does the media refer more to NBIX or ZTS?

Do analysts prefer NBIX or ZTS?

Which has more risk & volatility, NBIX or ZTS?

Do insiders & institutionals hold more shares of NBIX or ZTS?

Is NBIX or ZTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools